effect
manag
season
pandem
influenza
high
prioriti
intern
guidelin
mani
countri
recommend
antivir
treatment
older
peopl
individu
comorbid
increas
risk
complic
howev
antivir
often
prescrib
primari
care
europ
clinic
benefit
insuffici
demonstr
nonindustri
fund
pragmat
studi
alic
e
european
multin
multicentr
phase
iv
openlabel
nonindustri
fund
pragmat
adaptiveplatform
randomis
control
trial
rct
initi
trial
arm
best
usual
primari
care
best
usual
primari
care
plu
treatment
oseltamivir
five
day
aim
recruit
least
particip
year
old
present
influenzalik
ill
ili
symptom
durat
hour
primari
care
three
consecut
period
confirm
high
influenza
incid
particip
outcom
followedup
day
diari
telephon
primari
object
determin
whether
ad
antivir
treatment
best
usual
primari
care
effect
reduc
time
return
usual
daili
activ
fever
headand
muscleach
reduc
minor
sever
less
secondari
object
includ
determin
costeffect
benefit
subgroup
particip
accord
age
year
sever
symptom
low
medium
high
comorbid
yesno
durat
symptom
hour
decreas
peer
review
http
bmjopenbmjcomsiteaboutguidelinesxhtml
bmj
open
trial
registr
strength
limit
studi
alic
e
first
public
fund
multicountri
pragmat
studi
determin
whether
antivir
routin
prescrib
influenza
like
ill
ili
primari
care
alic
e
aim
go
beyond
determin
averag
treatment
effect
popul
determin
effect
patient
combin
prespecifi
characterist
age
symptom
durat
ill
sever
comorbid
platform
design
allow
studi
remain
relev
evolv
circumst
abil
add
treatment
arm
respons
adapt
allow
proport
particip
key
characterist
alloc
studi
arm
alter
cours
trial
accord
emerg
outcom
data
particip
inform
use
increas
chanc
receiv
intervent
effect
influenza
viru
highli
contagi
repres
common
caus
respiratori
infect
local
system
symptom
annual
influenza
epidem
account
consider
morbid
mortal
influenza
outbreak
potenti
becom
pandem
effect
control
manag
season
pandem
influenza
high
prioriti
nation
govern
routin
use
antivir
agent
rare
european
primari
care
gener
practition
gp
europ
usual
advis
patient
consult
influenzalik
ill
ili
take
paracetamol
nonsteroid
antiinflammatori
agent
nsaid
either
requir
regular
interv
may
also
provid
advic
overthecount
otc
medicin
selfmanag
ili
symptom
eg
maintain
fluid
bed
rest
take
time
work
school
broad
approach
current
consid
best
usual
care
empir
manag
ili
europ
current
suitabl
antivir
agent
avail
pragmat
evalu
alic
e
oseltamivir
neuraminidas
inhibitor
ni
us
food
drug
administr
fda
approv
oseltamivir
oseltamivir
classifi
essenti
medicin
mani
countri
stockpil
drug
ensur
readili
avail
treat
season
pandem
influenza
oseltamivir
phosphat
oral
prodrug
undergo
hydrolysi
hepat
esteras
form
activ
oseltamivir
carboxyl
oseltamivir
carboxyl
act
select
inhibit
influenza
b
viral
neuraminidas
enzym
normal
promot
releas
viru
infect
cell
cleav
termin
sialic
acid
residu
surfac
host
cell
influenza
viru
envelop
facilit
viral
movement
within
respiratori
tract
block
activ
enzym
oseltamivir
prevent
new
viral
particl
releas
oseltamivir
might
also
modifi
immun
respons
influenza
infect
reduc
level
proinflammatori
cytokin
might
turn
modul
symptom
influenza
industrysponsor
trial
studi
efficaci
studi
clinic
studi
report
ni
often
oseltamivir
subject
mani
systemat
review
metaanalys
includ
individu
patient
metaanalys
two
metaanalys
differ
methodolog
primari
outcom
measur
base
almost
set
trial
jefferson
et
al
found
oseltamivir
improv
mean
time
first
allevi
symptom
placebo
hour
dobson
et
al
found
oseltamivir
improv
median
time
allevi
symptom
placebo
hour
review
also
found
oseltamivir
reduc
risk
selfreport
nonverifi
pneumonia
clinic
diagnos
pneumonia
dobson
et
al
furthermor
indic
treatment
oseltamivir
might
reduc
risk
lower
respiratori
tract
infect
complic
hospit
patient
test
posit
influenza
howev
increas
nausea
vomit
found
like
associ
oseltamivir
use
even
possibl
reduct
symptomat
period
compar
placebo
valu
oseltamivir
treatment
previous
healthi
individu
nonsever
season
influenza
question
convers
circumst
individu
exampl
need
return
work
parent
carer
may
mean
reduct
functionlimit
symptom
day
may
huge
benefici
uk
academi
medic
scienc
recent
review
current
evid
advis
costeffect
analys
relat
virul
sever
symptom
circul
strain
consid
societ
perspect
need
inform
judgement
sinc
oseltamivir
gener
sale
excess
unit
state
stockpil
million
treatment
cost
unit
kingdom
spent
stockpil
million
dose
countri
possess
enough
oseltamivir
million
peopl
downgrad
oseltamivir
list
essenti
medicin
core
drug
one
complimentari
categori
drug
consid
less
costeffect
howev
never
largescal
intern
public
fund
pragmat
rct
costeffect
primari
care
evid
base
either
support
support
routin
use
agent
primari
care
inadequ
rais
question
effect
found
previou
efficaci
studi
translat
meaning
benefit
everi
day
primari
care
specif
overal
cost
benefit
possibl
shorten
symptom
durat
perspect
individu
suffer
health
servic
societi
patient
consid
higher
risk
complic
influenza
exampl
due
age
durat
sever
answer
question
reduc
import
clinic
uncertainti
primari
care
clinician
whether
prescrib
antivir
agent
ili
whether
prioritis
antivir
treatment
subgroup
primari
care
patient
alic
e
trial
deliv
work
packag
wp
platform
european
prepared
emerg
epidem
prepar
wwwprepareeuropeorg
consortium
grant
prepar
european
commiss
fund
network
rapid
effici
deliveri
harmonis
largescal
clinic
research
studi
infecti
diseas
id
alic
e
randomis
control
trial
investig
medicin
product
ctimp
primari
care
determin
clinicaland
costeffect
ad
antivir
agent
best
usual
primari
care
patient
specif
characterist
suffer
ili
thu
enabl
clinician
better
individualis
prescrib
decis
primari
object
alic
e
therefor
determin
whether
ad
antivir
treatment
best
usual
primari
care
effect
reduc
time
taken
return
usual
daili
activ
secondari
object
determin
whether
antivir
treatment
costeffect
benefit
prespecifi
subgroup
particip
decreas
hospit
admiss
decreas
complic
relat
ili
especi
pneumonia
improv
healthrel
qualiti
life
decreas
repeat
attend
gp
health
servic
decreas
time
first
reduct
time
allevi
newworsen
ili
symptom
reduc
use
counter
otc
prescrib
medic
includ
antibiot
affect
selfmanag
ili
symptom
protocol
alic
recommend
intervent
trial
spirit
guidelin
inform
consent
particip
studi
conduct
use
good
clinic
practic
guidelin
accord
principl
declar
helsinki
accord
relev
nation
guidelin
regul
act
independ
data
monitor
committe
dmc
review
efficaci
safeti
data
treatment
alloc
trial
steer
committe
provid
oversight
trial
network
particip
primari
care
clinic
research
network
european
countri
recruit
particip
figur
network
coordin
recruit
site
within
network
recruit
three
consecut
flu
season
season
start
end
recruit
base
local
influenzalik
ill
incid
rise
fall
prespecifi
threshold
use
inform
suppli
european
centr
diseas
prevent
control
ecdc
local
region
sourc
network
aim
recruit
minimum
particip
recruit
site
gp
practic
primari
care
hour
ooh
servic
paediatr
centr
within
primari
care
potenti
particip
identifi
present
recruit
site
symptom
ili
telephon
appoint
advic
symptom
particip
must
meet
inclus
criteria
includ
symptom
onset
hour
less
none
exclus
criteria
tabl
elig
will
particip
particip
complet
rest
initi
trial
procedur
either
within
visit
second
appoint
recruit
recruit
site
home
condit
treatment
associ
signific
impair
immun
eg
longterm
oral
steroid
chemotherapi
immun
disord
knownrecord
particip
clinic
record
opinion
respons
clinician
prescrib
immedi
antivir
treatment
local
implement
trial
builtin
flexibl
local
network
recruit
process
vari
exampl
medic
student
may
assist
recruit
task
certain
practic
other
incorpor
triag
system
addit
trial
specif
clinic
andor
research
support
staff
recruit
process
obtain
consent
particip
randomis
point
care
use
remot
onlin
electron
data
captur
edc
system
research
onlin
emerg
randomis
procedur
avail
webbas
facil
temporarili
unavail
randomis
initi
ratio
two
arm
stratif
subgroup
accord
ecdc
definit
higher
risk
complic
influenza
name
age
year
sever
symptom
low
medium
high
relev
comorbid
yesno
durat
symptom
sinc
onset
proport
randomis
studi
arm
may
alter
cours
trial
follow
prespecifi
bayesian
respons
adapt
approach
clinician
prescrib
placebo
credibl
compar
current
best
practic
therefor
unblind
code
break
requir
event
relev
emerg
howev
trial
team
blind
treatment
alloc
aggreg
level
recruit
creat
equipois
particip
two
arm
care
cover
trial
specif
train
arm
trial
support
routin
practic
previou
open
pragmat
trial
abl
minimis
placebo
effect
use
approach
particip
randomis
best
usual
primari
care
plu
oseltamivir
arm
given
dose
primari
outcom
patient
report
time
return
usual
daili
activ
fever
headach
muscleach
symptom
rate
problem
nonverb
children
clingi
replac
headach
muscl
ach
unansw
secondari
outcom
includ
collect
day
addit
clinic
examin
find
record
includ
temperatur
way
measur
oral
ear
axilla
use
antipyret
last
hour
puls
rate
weight
year
age
case
uncertainti
height
smoke
statu
gender
whether
flu
vaccin
within
six
month
pneumococc
vaccin
within
five
year
recruit
provid
antivir
medic
accord
particip
group
alloc
standardis
instruct
take
medic
recruit
also
take
oropharyng
nasal
swab
year
age
nasopharyng
swab
year
age
swab
place
univers
transport
media
utm
transport
local
laboratori
storag
final
instruct
particip
complet
symptom
diari
give
inform
telephon
followup
assess
requir
particip
attend
facetofac
followup
visit
part
studi
particip
subsequ
measur
ascertain
selfcomplet
diarybas
questionnair
telephon
call
local
trial
team
particip
legal
guardian
carer
ask
complet
symptom
particip
legal
guardian
telephon
day
three
one
day
day
one
defin
day
recruit
studi
offer
support
symptom
diari
complet
check
urgent
issu
also
telephon
day
day
ask
day
return
usual
daili
activ
fever
headand
muscleach
symptom
reduc
minor
sever
less
ensur
primari
end
point
collect
particip
ascertain
seriou
advers
event
sae
preced
two
week
particip
receiv
final
telephon
call
day
complet
verbal
va
answer
remain
question
symptom
resolut
need
trial
particip
consent
process
part
process
evalu
see
trial
team
ask
whether
particip
recurr
symptom
time
whether
admit
hospit
result
symptom
particip
visit
hospit
complic
possibl
relat
ili
chest
xray
primari
care
clinic
record
examin
trial
team
confirm
relev
diagnos
complic
includ
pneumonia
swab
receiv
local
laboratori
sampl
frozen
store
accept
deepfreez
flu
season
sampl
transport
laboratori
medic
microbiolog
univers
antwerp
belgium
analysi
particip
swab
analys
use
multiplex
rtpcr
detect
pathogen
gene
technolog
identifi
whether
particip
infect
influenza
b
respiratori
virus
ii
bacteria
iii
part
day
telephon
call
particip
legal
guardian
carer
question
ask
motiv
particip
alic
e
studi
influenc
decis
question
relat
research
particip
pandem
particip
clinician
ask
complet
brief
questionnair
subsampl
approxim
interview
use
semistructur
topic
guid
obtain
perspect
trial
process
view
influenza
manag
primari
care
particip
pandem
research
f
r
p
e
e
r
r
e
v
e
w
n
l
respons
adaptiveplatform
trial
design
adapt
platform
trial
enabl
multipl
intervent
indic
test
simultan
within
master
protocol
often
includ
capac
add
drop
studi
arm
studi
progress
platform
trial
provid
effect
framework
studi
patient
heterogen
outcom
goal
determin
best
treatment
variou
subgroup
patient
addit
platform
trial
design
incorpor
respons
adapt
random
order
random
particip
best
perform
intervent
cours
trial
increas
statist
power
effici
trial
well
lead
better
patient
outcom
cours
studi
chose
adapt
platform
trial
design
provid
flexibl
evalu
addit
intervent
trial
intervent
emerg
suitabl
pragmat
evalu
primari
care
addit
design
provid
abil
prospect
identifi
particular
subgroup
interest
may
receiv
benefit
antivir
agent
oppos
estim
singl
overal
effect
done
incorpor
bayesian
model
approach
combin
respons
adapt
random
base
prespecifi
particip
characterist
multipl
interim
analys
recruit
plan
everi
patient
flu
season
alic
e
particip
initi
randomis
ratio
two
arm
stratif
subgroup
random
block
arm
maintain
least
probabl
randomis
within
subgroup
throughout
cours
trial
arm
superior
assess
subgroup
may
declar
superior
subgroup
within
other
interim
analysi
arm
meet
superior
criterion
one
treatment
random
probabl
may
modifi
subgroup
minimum
particip
alloc
inferior
arm
remain
alloc
superior
arm
maximum
two
arm
event
stratif
block
longer
occur
within
subgroup
ensur
major
particip
receiv
bestknown
therapi
yet
trial
design
still
allow
assess
season
variat
popul
chang
studi
popul
time
addit
still
abl
collect
data
cost
health
relat
behaviour
includ
health
care
seek
associ
poorli
perform
arm
f
r
p
e
e
r
r
e
v
e
w
n
l
new
compar
arm
may
enter
trial
determin
trial
steer
committe
elig
therapi
includ
newli
approv
treatment
ili
therapi
recommend
public
health
agenc
influenza
pandem
arm
ad
trial
prespecifi
algorithm
determin
random
ratio
activ
respons
adapt
random
within
subgroup
respect
treatment
arm
oper
characterist
trial
updat
via
simul
howev
gener
structur
trial
chang
respons
adapt
random
may
activ
subgroup
without
satisfi
superior
criterion
number
intervent
greater
two
sampl
size
calcul
plan
design
avail
use
tradit
formula
instead
simul
must
use
estim
oper
characterist
adapt
algorithm
includ
estim
mani
particip
particular
characterist
requir
order
detect
differ
treatment
simul
prespecifi
algorithm
appli
random
particip
particular
prespecifi
characterist
depend
number
arm
collect
outcom
data
addit
algorithm
determin
arm
drop
futil
intervent
declar
superior
process
ad
new
intervent
platform
trial
particip
recruit
three
consecut
winter
rang
number
chosen
ensur
suffici
power
comparison
overal
popul
well
within
prespecifi
subgroup
given
natur
studi
adapt
design
desir
ensur
suffici
power
multipl
hypothes
across
sever
subgroup
number
particip
need
recruit
complex
multidimension
calcul
henc
numer
simul
conduct
calcul
power
variou
plausibl
scenario
maximum
target
particip
chosen
simul
gave
power
mani
subgroup
analys
one
day
benefit
term
symptom
relief
oseltamivir
particip
provid
power
compar
primari
end
point
overal
studi
popul
least
one
day
benefit
oseltamivir
particip
confirm
influenza
number
also
provid
power
subgroup
benefit
oseltamivir
particip
confirm
influenza
base
simul
primari
analysi
intent
treat
itt
includ
randomis
particip
treatment
arm
assign
regardless
treatment
taken
secondari
analys
includ
subset
itt
popul
confirm
influenza
accrual
trial
ongo
frequent
interim
analys
may
updat
random
probabl
depend
interim
result
number
arm
studi
composit
primari
endpoint
return
usual
activ
resolut
fever
muscleand
headach
minor
problem
less
model
accord
bayesian
piecewis
exponenti
model
surviv
time
model
allow
baselin
hazard
vari
across
followup
hazard
reach
primari
endpoint
model
four
time
interv
day
day
day
day
particip
reach
primari
endpoint
day
includ
particip
die
consid
censor
day
particip
withdraw
lost
followup
evalu
primari
endpoint
reason
consid
censor
last
contact
date
day
whichev
earlier
costeffect
analysi
cea
compar
direct
medic
cost
health
outcom
term
number
day
ili
limit
usual
activ
term
qualiti
adjust
life
year
gain
differ
arm
analysi
use
data
trial
resourc
use
va
score
relev
data
countri
trial
set
eg
unit
cost
type
health
care
provid
within
countri
potenti
differ
repeat
measur
va
arm
investig
perparticip
basi
use
mix
effect
model
valuat
qualiti
life
use
standard
instrument
measur
gener
health
statu
done
accord
guidelin
euroqol
group
use
crosswalk
index
valu
calcul
uncertainti
explor
use
bootstrap
repres
cloud
increment
costeffect
ratio
icer
costeffect
plane
well
costeffect
alic
e
trial
first
largescal
intern
nonindustri
sponsor
pragmat
randomis
trial
cost
effect
ad
oseltamivir
best
usual
primari
care
peopl
suffer
ili
open
trial
order
approxim
effect
condit
close
usual
care
order
determin
realworld
estim
cost
effect
lack
costeffect
analys
alongsid
clinic
trial
given
children
older
peopl
peopl
comorbid
underrepres
studi
done
highlight
decis
downgrad
statu
oseltamivir
despit
lack
trial
evid
model
list
essenti
medicin
state
use
oseltamivir
restrict
sever
ill
due
confirm
suspect
influenza
viru
infect
critic
ill
hospitalis
patient
anoth
report
quot
state
unless
new
inform
support
use
season
pandem
outbreak
provid
next
expert
committe
might
consid
oseltamivir
delet
current
uk
us
guidelin
recommend
treatment
defin
subgroup
frail
patient
patient
increas
risk
complic
evid
base
recommend
incomplet
withhold
treatment
patient
may
possibl
deni
benefit
includ
best
usual
primari
care
arm
studi
determin
ad
benefit
antivir
agent
current
practic
season
potenti
pandem
influenza
inform
great
import
deliveri
primari
care
ili
well
enhanc
evid
base
around
advoc
selfcar
mani
eu
countri
patient
ili
symptom
advis
consult
selfmanag
patient
addit
risk
factor
seldom
routin
treat
antivir
agent
larg
absenc
evid
costeffect
overal
subgroup
interest
virul
spread
type
circul
influenza
strain
vari
season
season
alic
e
aim
recruit
three
winterinfluenza
season
countri
therebi
obtain
wide
applic
data
furthermor
aim
includ
wide
agerang
particip
well
comorbid
addit
event
influenza
pandem
addit
intervent
arm
includ
decis
could
made
increas
maximum
sampl
size
adapt
design
offer
sever
advantag
tradit
studi
design
recruit
particular
arm
stop
predetermin
level
certainti
effect
noneffect
treatment
arm
reach
predefin
estim
precis
adapt
randomis
increas
chanc
particip
alloc
arm
inform
use
intervent
effect
lead
better
patient
care
better
patient
outcom
trial
progress
secondli
platform
design
allow
new
intervent
arm
ad
trial
benefit
comparison
exist
treatment
arm
head
head
way
flexibl
extend
potenti
pandem
situat
addit
altern
intervent
may
ad
accord
government
public
health
recommend
way
studi
remain
current
relev
clinic
practic
evolv
circumst
throughout
alic
e
novel
mani
way
provid
critic
inform
clinic
costeffect
ad
oseltamivir
best
known
ili
manag
condit
approxim
usual
care
overal
import
prespecifi
subgroup
alic
e
directli
impact
current
practic
either
confirm
best
usual
primari
care
lead
adapt
author
declar
compet
interest
f
r
p
e
e
r
r
e
v
e
w
n
l
f
r
p
e
e
r
r
e
v
e
w
n
l
alic
e
european
multin
multicentr
openlabel
nonindustri
fund
pragmat
adaptiveplatform
randomis
control
trial
rct
initi
trial
arm
best
usual
primari
care
best
usual
primari
care
plu
treatment
oseltamivir
five
day
aim
recruit
least
particip
year
old
present
influenzalik
ill
ili
symptom
durat
hour
primari
care
three
consecut
period
confirm
high
influenza
incid
particip
outcom
followedup
day
diari
telephon
primari
object
determin
whether
ad
antivir
treatment
best
usual
primari
care
effect
reduc
time
return
usual
daili
activ
fever
headand
muscleach
reduc
minor
sever
less
secondari
object
includ
estim
costeffect
benefit
subgroup
accord
age
year
sever
symptom
low
medium
high
comorbid
yesno
durat
symptom
hour
complic
hospit
admiss
pneumonia
use
addit
prescrib
medic
includ
antibiot
use
overthecount
medicin
selfmanag
ili
symptom
alic
e
first
public
fund
multicountri
pragmat
studi
determin
whether
antivir
routin
prescrib
influenza
like
ill
ili
primari
care
alic
e
aim
go
beyond
determin
averag
treatment
effect
popul
determin
effect
patient
combin
prespecifi
characterist
age
symptom
durat
ill
sever
comorbid
platform
design
allow
studi
remain
relev
evolv
circumst
abil
add
treatment
arm
respons
adapt
allow
proport
particip
key
characterist
alloc
studi
arm
alter
cours
trial
accord
emerg
outcom
data
particip
inform
use
increas
chanc
receiv
intervent
effect
industrysponsor
trial
studi
efficaci
studi
clinic
studi
report
ni
often
oseltamivir
subject
mani
systemat
review
metaanalys
includ
individu
patient
metaanalys
two
recent
metaanalys
differ
method
primari
outcom
measur
use
includ
almost
set
howev
increas
nausea
vomit
found
associ
oseltamivir
use
even
possibl
reduct
symptom
durat
compar
placebo
valu
oseltamivir
treatment
previous
healthi
individu
nonsever
season
influenza
question
convers
circumst
individu
exampl
urgent
need
return
work
parent
carer
may
mean
reduct
functionlimit
symptom
day
may
consid
worthwhil
uk
academi
medic
scienc
recent
review
current
evid
advis
costeffect
analys
take
virul
sever
circul
strain
account
form
societ
perspect
requir
inform
judgement
sinc
oseltamivir
gener
sale
excess
unit
state
stockpil
million
treatment
cost
unit
kingdom
spent
stockpil
million
dose
countri
possess
enough
oseltamivir
million
peopl
downgrad
oseltamivir
list
essenti
medicin
core
drug
one
complimentari
categori
drug
consid
less
costeffect
howev
never
largescal
intern
public
fund
pragmat
rct
costeffect
primari
care
evid
base
either
support
support
routin
use
agent
primari
care
inadequ
rais
question
effect
found
previou
efficaci
studi
translat
meaning
benefit
everi
day
primari
care
specif
overal
cost
benefit
possibl
shorten
symptom
durat
perspect
individu
suffer
health
servic
societi
patient
consid
higher
risk
complic
influenza
exampl
due
age
durat
sever
alic
e
randomis
control
trial
investig
medicin
product
ctimp
primari
care
determin
clinicaland
costeffect
ad
antivir
agent
best
usual
primari
care
patient
specif
characterist
suffer
ili
thu
enabl
clinician
better
individualis
prescrib
decis
primari
object
alic
e
therefor
determin
whether
ad
antivir
treatment
best
usual
primari
care
effect
reduc
time
taken
return
usual
daili
activ
secondari
object
determin
whether
antivir
treatment
costeffect
benefit
prespecifi
subgroup
particip
decreas
hospit
admiss
decreas
complic
relat
ili
especi
pneumonia
improv
healthrel
qualiti
life
decreas
repeat
attend
gp
health
servic
decreas
time
first
reduct
time
allevi
newworsen
ili
symptom
reduc
use
counter
otc
prescrib
medic
includ
antibiot
affect
selfmanag
ili
symptom
protocol
alic
manuscript
result
primari
outcom
publish
peerreview
journal
addit
manuscript
report
secondari
outcom
submit
public
peerreview
journal
intervent
arm
alic
e
use
antivir
addit
best
usual
primari
care
burden
particip
assess
tsc
consid
minim
antivir
current
assess
alic
e
oseltamivir
licens
medic
market
authoris
global
context
alic
e
trial
standard
dose
oseltamivir
shown
well
toler
studi
use
standard
oseltamivir
use
accord
market
authoris
grant
trial
particip
inform
trial
result
directli
howev
result
publish
prepar
consortium
websit
http
wwwprepareeuropeeu
nuffield
depart
primari
care
websit
http
wwwphcoxacukphctri
access
freeli
recruit
three
consecut
flu
season
season
start
end
recruit
base
report
local
influenzalik
ill
incid
rise
fall
prespecifi
threshold
use
inform
suppli
european
centr
diseas
prevent
control
ecdc
local
region
sourc
network
aim
recruit
minimum
particip
recruit
site
gp
practic
primari
care
hour
ooh
servic
paediatr
centr
within
primari
care
potenti
particip
identifi
present
recruit
site
symptom
ili
telephon
appoint
advic
symptom
particip
must
meet
inclus
criteria
includ
symptom
onset
hour
less
none
exclus
criteria
local
implement
trial
builtin
flexibl
local
network
recruit
process
vari
exampl
medic
student
may
assist
recruit
task
certain
practic
other
incorpor
triag
system
addit
trial
specif
clinic
andor
research
support
staff
recruit
process
clinician
prescrib
placebo
routin
care
credibl
compar
current
best
practic
therefor
unblind
code
break
requir
event
relev
emerg
howev
trial
team
blind
treatment
alloc
aggreg
level
recruit
promot
equipois
particip
two
arm
care
cover
trial
specif
train
arm
trial
support
routin
practic
previou
open
pragmat
trial
abl
minimis
placebo
effect
use
approach
intervent
particip
randomis
best
usual
primari
care
plu
oseltamivir
arm
given
dose
mg
oseltamivir
twice
day
five
day
oral
rout
capsul
year
year
year
dose
twice
daili
day
weight
measur
children
year
age
recruit
visit
medic
dose
particip
ask
weight
baselin
assess
measur
case
uncertainti
daili
symptom
diari
subsequ
day
telephon
call
use
monitor
intervent
complianc
togeth
telephon
call
day
also
ascertain
minim
data
set
outcom
primari
outcom
patient
report
time
return
usual
daili
activ
fever
headach
muscleach
symptom
rate
problem
nonverb
children
clingi
replac
headach
muscl
ach
unansw
secondari
outcom
includ
collect
day
obtain
written
inform
consent
recruit
complet
baselin
case
report
form
crf
includ
requir
inform
randomis
age
relev
comorbid
durat
symptom
clinician
rate
sever
ili
mild
moder
sever
addit
crf
ascertain
participantspar
sever
grade
type
health
care
coverag
eg
public
privat
mix
symptom
question
supplement
childspecif
question
canadian
acut
respiratori
ill
flu
scale
complet
children
year
age
addit
clinic
examin
find
record
includ
temperatur
way
measur
oral
ear
axilla
use
antipyret
last
hour
puls
rate
weight
year
age
case
uncertainti
height
smoke
statu
gender
whether
flu
vaccin
within
six
month
pneumococc
vaccin
within
five
year
recruit
provid
antivir
medic
accord
particip
group
alloc
standardis
instruct
take
medic
recruit
also
take
oropharyng
nasal
swab
year
age
nasopharyng
swab
year
age
swab
place
univers
transport
media
utm
transport
local
laboratori
storag
final
instruct
particip
complet
symptom
diari
give
inform
telephon
followup
assess
requir
particip
attend
facetofac
followup
visit
part
studi
particip
subsequ
measur
ascertain
selfcomplet
diarybas
questionnair
telephon
call
local
trial
team
particip
legal
guardian
carer
ask
complet
symptom
diari
day
baselin
day
randomis
follow
data
point
collect
expect
treatment
benefit
ethnic
employ
statu
cohabit
pregnanc
stage
current
longterm
medic
follow
data
point
collect
daili
diari
sever
select
ili
symptom
qualiti
life
eq
visual
analogu
scale
va
return
usual
daili
activ
prescript
medic
use
includ
antibiot
use
otc
medic
remedi
adher
trial
medic
potenti
sideeffect
day
follow
data
point
collect
weekli
qualiti
life
use
eq
index
respond
year
eq
respond
year
effect
particip
symptom
usual
daili
activ
health
care
resourc
use
outofpocket
expenditur
ili
state
peopl
household
particip
legal
guardian
telephon
day
three
one
day
day
one
defin
day
recruit
studi
offer
support
symptom
diari
complet
check
urgent
issu
also
telephon
day
swab
receiv
local
laboratori
sampl
frozen
store
accept
deepfreez
flu
season
sampl
transport
laboratori
medic
microbiolog
univers
antwerp
belgium
analysi
particip
swab
analys
use
multiplex
rtpcr
detect
pathogen
gene
technolog
identifi
whether
particip
infect
influenza
b
respiratori
virus
ii
bacteria
iii
part
day
telephon
call
particip
legal
guardian
carer
question
ask
motiv
particip
alic
e
studi
influenc
decis
question
relat
research
particip
pandem
particip
clinician
ask
complet
brief
questionnair
subsampl
ask
perspect
trial
process
view
influenza
manag
primari
care
particip
pandem
research
oseltamivir
welldocu
safeti
profil
commonli
use
medic
primari
care
set
result
nonseri
advers
event
record
studi
seriou
advers
event
sae
occur
day
particip
enrol
trial
record
left
investig
clinic
judgment
decid
whether
symptom
side
effect
suffici
sever
requir
particip
remov
treatment
particip
withdrawn
due
advers
event
ae
investig
arrang
followup
visit
telephon
call
advers
event
resolv
stabilis
end
trial
particip
whichev
later
particip
withdrawn
due
ae
follow
data
continu
collect
inform
includ
purpos
intent
treat
analysi
particip
right
withdraw
studi
time
without
prejudic
current
futur
health
care
adapt
platform
trial
enabl
multipl
intervent
indic
test
simultan
within
master
protocol
often
includ
capac
add
drop
studi
arm
studi
progress
platform
trial
provid
effect
framework
studi
patient
heterogen
outcom
goal
determin
best
treatment
variou
subgroup
patient
addit
platform
trial
design
incorpor
respons
adapt
random
order
random
particip
best
perform
intervent
cours
trial
increas
statist
power
effici
trial
well
lead
better
patient
outcom
cours
studi
chose
adapt
platform
trial
design
provid
flexibl
evalu
addit
intervent
trial
intervent
emerg
suitabl
pragmat
evalu
primari
care
addit
design
provid
abil
prospect
identifi
particular
subgroup
interest
may
receiv
benefit
antivir
agent
oppos
estim
singl
overal
effect
done
incorpor
bayesian
model
approach
combin
respons
adapt
random
base
prespecifi
alic
e
particip
initi
randomis
ratio
two
arm
stratif
subgroup
random
block
arm
maintain
least
probabl
randomis
within
subgroup
throughout
cours
trial
arm
superior
assess
subgroup
may
declar
superior
subgroup
within
other
interim
analysi
arm
meet
superior
criterion
one
treatment
random
probabl
may
modifi
subgroup
minimum
particip
alloc
inferior
arm
remain
alloc
superior
arm
maximum
two
arm
event
stratif
block
longer
occur
within
subgroup
ensur
major
particip
receiv
bestknown
therapi
yet
trial
design
still
allow
assess
season
variat
popul
chang
studi
popul
time
addit
still
abl
collect
data
cost
health
relat
behaviour
includ
health
care
seek
associ
poorli
perform
arm
new
compar
arm
may
enter
trial
determin
trial
steer
committe
elig
therapi
includ
newli
approv
treatment
ili
therapi
recommend
public
health
agenc
influenza
pandem
arm
ad
trial
prespecifi
algorithm
determin
random
ratio
activ
respons
adapt
random
within
subgroup
respect
treatment
arm
oper
characterist
trial
updat
via
simul
howev
gener
structur
trial
chang
respons
adapt
random
may
activ
subgroup
without
satisfi
superior
criterion
number
intervent
greater
two
sampl
size
calcul
plan
design
avail
use
tradit
formula
instead
simul
must
use
estim
oper
characterist
adapt
algorithm
includ
estim
mani
particip
particular
characterist
requir
order
detect
differ
treatment
simul
prespecifi
algorithm
appli
random
particip
particular
prespecifi
characterist
depend
number
arm
collect
outcom
data
addit
algorithm
determin
arm
drop
futil
particip
recruit
three
consecut
winter
rang
chosen
ensur
suffici
power
comparison
overal
popul
well
within
prespecifi
subgroup
given
natur
studi
adapt
design
desir
ensur
suffici
power
multipl
hypothes
across
sever
subgroup
number
particip
need
recruit
complex
multidimension
calcul
henc
numer
simul
conduct
calcul
power
variou
plausibl
scenario
maximum
target
particip
chosen
simul
gave
power
mani
subgroup
analys
one
day
benefit
term
symptom
relief
oseltamivir
particip
provid
power
compar
primari
end
point
overal
studi
popul
least
one
day
benefit
oseltamivir
particip
confirm
influenza
number
also
provid
power
subgroup
benefit
oseltamivir
particip
confirm
influenza
base
simul
assumpt
patient
confirm
influenza
patient
ili
origin
anoth
viral
infect
primari
analysi
intent
treat
itt
includ
randomis
particip
treatment
arm
assign
regardless
treatment
taken
secondari
analys
includ
subset
itt
popul
confirm
influenza
least
one
interim
analysi
accrual
data
collect
season
complet
recruit
open
subsequ
flu
season
accrual
rapid
larg
number
patient
enrol
exampl
case
flu
pandem
one
interim
analysi
may
conduct
flu
season
occur
approxim
addit
patient
enrol
adapt
randomis
probabl
may
updat
arm
assess
superior
interim
analysi
composit
primari
endpoint
return
usual
activ
resolut
fever
muscleand
headach
minor
problem
less
model
accord
bayesian
piecewis
exponenti
model
surviv
time
model
allow
baselin
hazard
vari
across
followup
hazard
reach
primari
endpoint
model
four
time
interv
day
day
day
day
particip
reach
primari
endpoint
day
includ
particip
die
consid
censor
day
particip
withdraw
lost
followup
evalu
primari
endpoint
reason
consid
censor
last
contact
date
day
whichev
earlier
costeffect
analysi
cea
compar
direct
medic
cost
health
outcom
term
number
day
ili
limit
usual
activ
term
qualiti
adjust
life
year
gain
differ
arm
analysi
use
data
trial
resourc
use
va
score
relev
data
countri
trial
set
eg
unit
cost
type
health
care
provid
within
countri
potenti
differ
repeat
measur
va
arm
investig
perparticip
basi
use
mix
effect
model
valuat
qualiti
life
use
standard
instrument
measur
gener
health
statu
done
accord
guidelin
euroqol
group
use
crosswalk
index
valu
calcul
uncertainti
explor
use
bootstrap
repres
cloud
increment
costeffect
ratio
icer
costeffect
plane
well
costeffect
accept
curv
subgroup
analys
perform
acknowledg
heterogen
within
arm
trial
eg
age
sever
countri
valu
perfect
inform
analysi
may
also
perform
identifi
sourc
uncertainti
reduc
addit
research
effici
improv
decis
make
alic
e
trial
first
largescal
intern
nonindustri
sponsor
pragmat
randomis
trial
cost
effect
ad
oseltamivir
best
usual
primari
care
peopl
suffer
ili
anoth
report
quot
state
unless
new
inform
support
use
season
pandem
outbreak
provid
next
expert
committe
might
consid
oseltamivir
delet
current
uk
us
guidelin
recommend
treatment
defin
subgroup
frail
patient
patient
increas
risk
complic
evid
base
recommend
incomplet
withhold
treatment
patient
may
possibl
deni
benefit
includ
best
usual
primari
care
arm
studi
determin
ad
benefit
antivir
agent
current
practic
season
potenti
pandem
influenza
inform
great
import
deliveri
primari
care
ili
well
enhanc
evid
base
around
advoc
selfcar
mani
countri
patient
ili
symptom
advis
consult
selfmanag
patient
addit
risk
factor
seldom
routin
treat
antivir
agent
larg
absenc
evid
costeffect
overal
subgroup
interest
virul
spread
type
circul
influenza
strain
vari
season
season
alic
e
aim
recruit
three
winterinfluenza
season
countri
therebi
obtain
wide
applic
data
allow
us
determin
whether
benefit
otherwis
antivir
agent
influenc
season
furthermor
aim
includ
wide
agerang
particip
well
comorbid
addit
event
influenza
adapt
design
offer
sever
advantag
tradit
studi
design
recruit
particular
arm
stop
predetermin
level
certainti
effect
noneffect
treatment
arm
reach
predefin
estim
precis
adapt
randomis
increas
chanc
particip
alloc
arm
inform
use
intervent
effect
lead
better
patient
care
better
patient
outcom
trial
progress
secondli
platform
design
allow
new
intervent
arm
ad
trial
benefit
comparison
exist
treatment
arm
head
head
way
flexibl
extend
potenti
pandem
situat
addit
altern
intervent
may
ad
accord
government
public
health
recommend
way
studi
remain
current
relev
clinic
practic
evolv
circumst
throughout
alic
e
novel
mani
way
provid
critic
inform
clinic
costeffect
ad
oseltamivir
best
current
ili
manag
condit
approxim
usual
care
overal
well
import
prespecifi
subgroup
alic
e
like
therefor
enhanc
evid
base
support
import
common
area
clinic
practic
author
declar
compet
interest
work
support
european
commiss
programm
grant
number
particip
timelin
time
schedul
enrol
intervent
includ
runin
washout
assess
visit
particip
schemat
diagram
highli
recommend
see
figur
definit
analysi
popul
relat
protocol
nonadher
eg
randomis
analysi
statist
method
handl
miss
data
eg
multipl
imput
data
monitor
composit
data
monitor
committe
dmc
summari
role
report
structur
statement
whether
independ
sponsor
compet
interest
refer
detail
charter
found
protocol
altern
explan
dmc
need
descript
interim
analys
stop
guidelin
includ
access
interim
result
make
final
decis
termin
trial
pragmat
adaptiveplatform
randomis
control
trial
rct
initi
trial
arm
best
usual
primari
care
best
usual
primari
care
plu
treatment
oseltamivir
five
day
aim
recruit
least
particip
year
old
present
influenzalik
ill
ili
symptom
durat
hour
primari
care
three
consecut
period
confirm
high
influenza
incid
particip
outcom
followedup
day
diari
telephon
primari
object
determin
whether
ad
antivir
treatment
best
usual
primari
care
effect
reduc
time
return
usual
daili
activ
fever
headand
muscleach
reduc
minor
sever
less
secondari
object
includ
estim
costeffect
benefit
subgroup
accord
age
year
sever
symptom
present
low
medium
high
comorbid
yesno
durat
symptom
hour
complic
hospit
admiss
pneumonia
use
addit
prescrib
medic
includ
antibiot
use
overthecount
medicin
selfmanag
ili
symptom
sever
comorbid
influenc
outcom
platform
design
allow
studi
remain
relev
evolv
circumst
abil
add
treatment
arm
respons
adapt
allow
proport
particip
key
characterist
alloc
studi
arm
alter
cours
trial
accord
emerg
outcom
data
particip
inform
use
increas
chanc
receiv
intervent
effect
answer
question
reduc
import
clinic
uncertainti
primari
care
clinician
whether
prescrib
antivir
agent
ili
whether
prioritis
antivir
treatment
subgroup
primari
care
patient
alic
e
trial
deliv
work
packag
wp
platform
european
prepared
emerg
epidem
prepar
wwwprepareeuropeeu
consortium
grant
prepar
european
commiss
fund
network
rapid
effici
deliveri
harmonis
largescal
clinic
research
studi
infecti
diseas
id
alic
e
randomis
control
trial
investig
medicin
product
ctimp
primari
care
determin
clinicaland
costeffect
ad
antivir
agent
best
usual
primari
care
patient
specif
characterist
suffer
ili
thu
enabl
clinician
better
individualis
prescrib
decis
primari
object
alic
e
therefor
determin
whether
ad
antivir
treatment
best
usual
primari
care
effect
reduc
time
taken
return
usual
daili
activ
patient
ili
secondari
object
determin
whether
antivir
treatment
costeffect
benefit
prespecifi
subgroup
particip
decreas
hospit
admiss
decreas
complic
relat
ili
especi
pneumonia
improv
healthrel
qualiti
life
decreas
repeat
attend
gp
health
servic
decreas
time
first
reduct
time
allevi
newworsen
ili
symptom
reduc
use
counter
otc
prescrib
medic
includ
antibiot
affect
selfmanag
ili
symptom
protocol
alic
recommend
intervent
trial
spirit
guidelin
trial
grant
research
ethic
committe
rec
approv
nre
committe
particip
provid
written
inform
consent
particip
studi
conduct
use
good
clinic
practic
guidelin
accord
principl
declar
helsinki
accord
relev
nation
guidelin
regul
act
independ
data
monitor
committe
dmc
review
efficaci
safeti
data
treatment
alloc
trial
steer
committe
provid
oversight
trial
manuscript
result
primari
outcom
publish
peerreview
journal
addit
manuscript
report
secondari
outcom
submit
public
peerreview
journal
intervent
arm
alic
e
use
antivir
addit
best
usual
primari
care
burden
particip
assess
tsc
consid
minim
antivir
current
assess
alic
e
oseltamivir
licens
medic
market
authoris
global
context
alic
e
trial
standard
dose
oseltamivir
shown
well
toler
studi
use
standard
oseltamivir
use
accord
market
authoris
grant
trial
particip
inform
trial
result
directli
howev
result
publish
prepar
recruit
three
consecut
flu
season
season
start
end
recruit
base
report
local
influenzalik
ill
incid
rise
fall
prespecifi
threshold
use
inform
suppli
european
centr
diseas
prevent
control
ecdc
local
region
sourc
network
aim
recruit
minimum
particip
recruit
site
gp
practic
primari
care
hour
ooh
servic
paediatr
centr
within
primari
care
potenti
particip
identifi
present
recruit
site
symptom
ili
telephon
appoint
advic
symptom
particip
must
meet
inclus
criteria
includ
symptom
onset
hour
less
none
exclus
criteria
tabl
definit
ili
use
alic
e
base
european
centr
diseas
prevent
control
ecdc
definit
flexibl
maximis
recruit
children
elderli
elig
will
particip
particip
complet
rest
initi
trial
procedur
either
within
visit
second
appoint
recruit
recruit
site
home
local
implement
trial
builtin
flexibl
local
network
recruit
process
vari
exampl
medic
student
may
assist
recruit
task
certain
practic
other
incorpor
triag
system
addit
trial
specif
clinic
andor
research
support
staff
recruit
process
obtain
inform
written
consent
particip
randomis
point
care
use
remot
onlin
electron
data
captur
edc
system
research
onlin
emerg
randomis
procedur
avail
webbas
facil
temporarili
unavail
randomis
initi
ratio
two
arm
stratif
subgroup
accord
ecdc
definit
higher
risk
complic
influenza
name
age
year
sever
symptom
low
medium
high
relev
comorbid
yesno
durat
symptom
sinc
onset
proport
randomis
studi
arm
may
alter
cours
trial
follow
prespecifi
bayesian
respons
adapt
approach
clinician
prescrib
placebo
routin
care
credibl
compar
current
best
practic
therefor
unblind
code
break
requir
event
relev
emerg
howev
trial
team
blind
treatment
alloc
aggreg
level
recruit
promot
equipois
particip
two
arm
care
cover
trial
specif
train
arm
trial
support
routin
practic
previou
open
pragmat
trial
abl
minimis
placebo
effect
use
approach
intervent
particip
randomis
best
usual
primari
care
plu
oseltamivir
arm
given
dose
mg
oseltamivir
twice
day
five
day
oral
rout
capsul
year
year
year
dose
twice
daili
day
weight
measur
children
year
age
recruit
visit
medic
dose
particip
ask
weight
baselin
assess
measur
case
uncertainti
daili
symptom
diari
subsequ
day
telephon
call
use
monitor
intervent
complianc
togeth
telephon
call
day
also
ascertain
minim
data
set
outcom
primari
outcom
patient
report
time
return
usual
daili
activ
fever
headach
muscleach
symptom
rate
problem
nonverb
children
clingi
replac
headach
muscl
ach
unansw
secondari
outcom
includ
collect
day
obtain
written
inform
consent
recruit
complet
baselin
case
report
form
crf
includ
requir
inform
randomis
age
relev
comorbid
durat
symptom
clinician
rate
sever
ili
mild
moder
sever
addit
crf
ascertain
participantspar
sever
grade
type
health
care
coverag
eg
public
privat
mix
symptom
question
supplement
childspecif
question
canadian
acut
respiratori
ill
flu
scale
complet
children
year
age
addit
clinic
examin
find
record
includ
temperatur
way
measur
oral
ear
axilla
use
antipyret
last
hour
puls
rate
weight
year
age
case
uncertainti
height
smoke
statu
gender
whether
flu
vaccin
within
six
month
pneumococc
vaccin
within
five
year
recruit
provid
antivir
medic
accord
particip
group
alloc
standardis
instruct
take
medic
recruit
also
take
oropharyng
nasal
swab
year
age
nasopharyng
swab
year
age
swab
place
univers
transport
media
utm
transport
local
laboratori
storag
final
instruct
particip
complet
symptom
diari
give
inform
telephon
followup
assess
requir
particip
attend
facetofac
followup
visit
part
studi
particip
subsequ
measur
ascertain
selfcomplet
diarybas
questionnair
telephon
call
local
trial
team
particip
legal
guardian
carer
ask
complet
symptom
diari
day
baselin
day
randomis
follow
data
point
collect
expect
treatment
benefit
ethnic
employ
statu
cohabit
pregnanc
stage
current
longterm
medic
follow
data
point
collect
daili
diari
sever
select
ili
symptom
qualiti
life
eq
visual
analogu
scale
va
return
usual
daili
activ
prescript
medic
use
includ
antibiot
use
otc
medic
remedi
adher
trial
medic
potenti
sideeffect
day
follow
data
point
collect
weekli
qualiti
life
use
eq
index
respond
year
eq
respond
year
effect
particip
symptom
usual
daili
activ
health
care
resourc
use
outofpocket
expenditur
ili
state
peopl
household
particip
legal
guardian
telephon
day
three
one
day
day
one
defin
day
recruit
studi
offer
support
symptom
diari
complet
check
urgent
issu
also
telephon
day
swab
receiv
local
laboratori
sampl
frozen
store
accept
deepfreez
flu
season
sampl
transport
laboratori
medic
microbiolog
univers
antwerp
belgium
analysi
particip
swab
analys
use
multiplex
rtpcr
detect
pathogen
gene
technolog
identifi
whether
particip
infect
influenza
b
respiratori
virus
ii
bacteria
iii
part
day
telephon
call
particip
legal
guardian
carer
question
ask
motiv
particip
alic
e
studi
influenc
decis
question
relat
research
particip
pandem
particip
clinician
ask
complet
brief
questionnair
subsampl
ask
perspect
trial
process
view
influenza
manag
primari
care
particip
pandem
research
oseltamivir
welldocu
safeti
profil
commonli
use
medic
primari
care
set
result
nonseri
advers
event
record
studi
seriou
advers
event
sae
occur
day
particip
enrol
trial
record
left
investig
clinic
judgment
decid
whether
symptom
side
effect
suffici
sever
requir
particip
remov
treatment
particip
withdrawn
due
advers
event
ae
investig
arrang
followup
visit
telephon
call
advers
event
resolv
stabilis
end
trial
particip
whichev
later
particip
withdrawn
due
ae
follow
data
continu
collect
inform
includ
purpos
intent
treat
analysi
particip
right
withdraw
studi
time
without
prejudic
current
futur
health
care
adapt
platform
trial
enabl
multipl
intervent
indic
test
simultan
within
master
protocol
often
includ
capac
add
drop
studi
arm
studi
progress
platform
trial
provid
effect
framework
studi
patient
heterogen
outcom
goal
determin
best
treatment
variou
subgroup
patient
addit
platform
trial
design
incorpor
respons
adapt
random
order
random
particip
best
perform
intervent
cours
trial
increas
statist
power
effici
trial
well
lead
better
patient
outcom
cours
studi
chose
adapt
platform
trial
design
provid
flexibl
evalu
addit
intervent
trial
intervent
emerg
suitabl
pragmat
evalu
primari
care
addit
design
provid
abil
prospect
identifi
particular
subgroup
interest
may
receiv
benefit
antivir
agent
oppos
estim
singl
overal
effect
done
incorpor
bayesian
model
approach
combin
respons
adapt
random
base
prespecifi
alic
e
particip
initi
randomis
ratio
two
arm
stratif
subgroup
random
block
arm
maintain
least
probabl
randomis
within
subgroup
throughout
cours
trial
arm
superior
assess
subgroup
may
declar
superior
subgroup
within
other
interim
analysi
arm
meet
superior
criterion
one
treatment
random
probabl
may
modifi
subgroup
minimum
particip
alloc
inferior
arm
remain
alloc
superior
arm
maximum
two
arm
event
stratif
block
longer
occur
within
subgroup
ensur
major
particip
receiv
bestknown
therapi
yet
trial
design
still
allow
assess
season
variat
popul
chang
studi
popul
time
addit
still
abl
collect
data
cost
health
relat
behaviour
includ
health
care
seek
associ
poorli
perform
arm
new
compar
arm
may
enter
trial
determin
trial
steer
committe
elig
therapi
includ
newli
approv
treatment
ili
therapi
recommend
public
health
agenc
influenza
pandem
arm
ad
trial
prespecifi
algorithm
determin
random
ratio
activ
respons
adapt
random
within
subgroup
respect
treatment
arm
oper
characterist
trial
updat
via
simul
howev
gener
structur
trial
chang
respons
adapt
random
may
activ
subgroup
without
satisfi
superior
criterion
number
intervent
greater
two
sampl
size
calcul
plan
design
avail
use
tradit
formula
instead
simul
must
use
estim
oper
characterist
adapt
algorithm
includ
estim
mani
particip
particular
characterist
requir
order
detect
differ
treatment
simul
prespecifi
algorithm
appli
random
particip
particular
prespecifi
characterist
depend
number
arm
collect
outcom
data
addit
algorithm
determin
arm
drop
futil
f
r
p
e
e
r
r
e
v
e
w
n
l
intervent
declar
superior
process
ad
new
intervent
platform
trial
particip
recruit
three
consecut
winter
rang
chosen
ensur
suffici
power
comparison
overal
popul
well
within
prespecifi
subgroup
given
natur
studi
adapt
design
desir
ensur
suffici
power
multipl
hypothes
across
sever
subgroup
number
particip
need
recruit
complex
multidimension
calcul
henc
numer
simul
conduct
calcul
power
variou
plausibl
scenario
maximum
target
particip
chosen
simul
gave
power
mani
subgroup
analys
one
day
benefit
term
symptom
relief
oseltamivir
particip
provid
power
compar
primari
end
point
overal
studi
popul
least
one
day
benefit
oseltamivir
particip
confirm
influenza
number
also
provid
power
subgroup
benefit
oseltamivir
particip
confirm
influenza
base
simul
assumpt
patient
confirm
influenza
patient
ili
origin
anoth
viral
infect
primari
analysi
intent
treat
itt
includ
randomis
particip
treatment
arm
assign
regardless
treatment
taken
secondari
analys
includ
subset
itt
popul
confirm
influenza
least
one
interim
analysi
accrual
data
collect
season
complet
recruit
open
subsequ
flu
season
accrual
rapid
larg
number
patient
enrol
exampl
case
flu
pandem
one
interim
analysi
may
conduct
flu
season
occur
approxim
addit
patient
enrol
adapt
randomis
probabl
may
updat
arm
assess
superior
interim
analysi
composit
primari
endpoint
return
usual
activ
resolut
fever
muscleand
headach
minor
problem
less
model
accord
bayesian
piecewis
exponenti
model
surviv
time
model
allow
baselin
hazard
vari
across
followup
hazard
reach
primari
endpoint
model
f
r
p
e
e
r
r
e
v
e
w
n
l
four
time
interv
day
day
day
day
particip
reach
primari
endpoint
day
includ
particip
die
consid
censor
day
particip
withdraw
lost
followup
evalu
primari
endpoint
reason
consid
censor
last
contact
date
day
whichev
earlier
costeffect
analysi
cea
compar
direct
medic
cost
health
outcom
term
number
day
ili
limit
usual
activ
term
qualiti
adjust
life
year
gain
differ
arm
analysi
use
data
trial
resourc
use
va
score
relev
data
countri
trial
set
eg
unit
cost
type
health
care
provid
within
countri
potenti
differ
repeat
measur
va
arm
investig
perparticip
basi
use
mix
effect
model
valuat
qualiti
life
use
standard
instrument
measur
gener
health
statu
done
accord
guidelin
euroqol
group
use
crosswalk
index
valu
calcul
uncertainti
explor
use
bootstrap
repres
cloud
increment
costeffect
ratio
icer
costeffect
plane
well
costeffect
accept
curv
subgroup
analys
perform
acknowledg
heterogen
within
arm
trial
eg
age
sever
countri
valu
perfect
inform
analysi
may
also
perform
identifi
sourc
uncertainti
reduc
addit
research
effici
improv
decis
make
alic
e
trial
first
largescal
intern
nonindustri
sponsor
pragmat
randomis
trial
cost
effect
ad
oseltamivir
best
usual
primari
care
peopl
suffer
ili
anoth
report
quot
state
unless
new
inform
support
use
season
pandem
outbreak
provid
next
expert
committe
might
consid
oseltamivir
delet
current
uk
us
guidelin
recommend
treatment
defin
subgroup
frail
patient
patient
increas
risk
complic
evid
base
recommend
incomplet
withhold
treatment
patient
may
possibl
deni
benefit
includ
best
usual
primari
care
arm
studi
determin
ad
benefit
antivir
agent
current
practic
season
potenti
pandem
influenza
inform
great
import
deliveri
primari
care
ili
well
enhanc
evid
base
around
advoc
selfcar
mani
countri
patient
ili
symptom
advis
consult
selfmanag
patient
addit
risk
factor
seldom
routin
treat
antivir
agent
larg
absenc
evid
costeffect
overal
subgroup
interest
virul
spread
type
circul
influenza
strain
vari
season
season
alic
e
aim
recruit
three
winterinfluenza
season
countri
therebi
obtain
wide
applic
data
allow
us
determin
whether
benefit
otherwis
antivir
agent
influenc
season
furthermor
aim
includ
wide
agerang
particip
mani
differ
set
well
comorbid
addit
flexibl
extend
potenti
pandem
situat
addit
altern
intervent
may
ad
accord
government
public
health
recommend
way
studi
remain
current
relev
clinic
practic
evolv
circumst
throughout
alic
e
novel
mani
way
provid
critic
inform
clinic
costeffect
ad
oseltamivir
best
current
ili
manag
condit
approxim
usual
care
overal
well
import
prespecifi
subgroup
alic
e
like
therefor
enhanc
evid
base
support
import
common
area
clinic
practic
author
declar
compet
interest
work
support
european
commiss
programm
grant
number
role
studi
sponsor
funder
studi
design
collect
manag
analysi
interpret
data
write
report
decis
submit
report
public
includ
whether
ultim
author
activ
na
composit
role
respons
coordin
centr
steer
committe
endpoint
adjud
committe
data
manag
team
individu
group
overse
trial
applic
see
item
data
monitor
committe
primari
secondari
outcom
includ
specif
measur
variabl
eg
systol
blood
pressur
analysi
metric
eg
chang
baselin
final
valu
time
event
method
aggreg
eg
median
proport
time
point
outcom
explan
clinic
relev
chosen
efficaci
harm
outcom
strongli
recommend
particip
timelin
time
schedul
enrol
intervent
includ
runin
washout
assess
visit
particip
schemat
diagram
highli
recommend
see
figur
alloc
sequenc
gener
method
gener
alloc
sequenc
eg
computergener
random
number
list
factor
stratif
reduc
predict
random
sequenc
detail
plan
restrict
eg
block
provid
separ
document
unavail
enrol
particip
assign
intervent
alloc
conceal
mechan
mechan
implement
alloc
sequenc
eg
central
telephon
sequenti
number
opaqu
seal
envelop
describ
step
conceal
sequenc
intervent
assign
implement
gener
alloc
sequenc
enrol
particip
assign
particip
intervent
blind
mask
blind
assign
intervent
eg
trial
particip
care
provid
outcom
assessor
data
analyst
blind
circumst
unblind
permiss
procedur
reveal
particip
alloc
intervent
trial
data
collect
method
plan
assess
collect
outcom
baselin
trial
data
includ
relat
process
promot
data
qualiti
eg
duplic
measur
train
assessor
descript
studi
instrument
eg
questionnair
laboratori
test
along
reliabl
valid
known
refer
data
collect
form
found
protocol
plan
promot
particip
retent
complet
followup
includ
list
outcom
data
collect
particip
discontinu
deviat
intervent
protocol
definit
analysi
popul
relat
protocol
nonadher
eg
randomis
analysi
statist
method
handl
miss
data
eg
multipl
imput
data
monitor
composit
data
monitor
committe
dmc
summari
role
report
structur
statement
whether
independ
sponsor
compet
interest
refer
detail
charter
found
protocol
altern
explan
dmc
need
descript
interim
analys
stop
guidelin
includ
access
interim
result
make
final
decis
termin
trial
person
inform
potenti
enrol
particip
collect
share
maintain
order
protect
confidenti
trial
declar
interest
financi
compet
interest
princip
investig
overal
trial
studi
site
access
data
statement
access
final
trial
dataset
disclosur
contractu
agreement
limit
access
investig
